Home » Dual Submissions for Postmarket Studies Needed Under Draft Guidance
Dual Submissions for Postmarket Studies Needed Under Draft Guidance
July 15, 2008
Sponsors of postmarket trials who submit electronic reports of adverse events will have to submit them to two separate U.S. Food and Drug Administration (FDA) offices if a draft guidance is implemented.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor